These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32195008)

  • 1. The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC.
    Stafford M; Kaczmar J
    Cancers Head Neck; 2020; 5():4. PubMed ID: 32195008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
    Shibata H; Saito S; Uppaluri R
    Front Oncol; 2021; 11():727433. PubMed ID: 34552878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
    Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
    Front Immunol; 2022; 13():970823. PubMed ID: 36389668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
    Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
    Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients.
    Tian Y; Zhang L; Jin N; Wan Z; Zhang H; Zhang H; Zhang L
    Onco Targets Ther; 2022; 15():353-359. PubMed ID: 35422629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
    Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
    Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.
    Saito S; Shibata H; Adkins D; Uppaluri R
    Curr Otorhinolaryngol Rep; 2022 Mar; 10(1):108-115. PubMed ID: 35990387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
    Cabezas-Camarero S; Pérez-Segura P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response.
    Olmos M; Glajzer J; Büntemeyer TO; Frohwitter G; Ries J; Eckstein M; Hecht M; Lutz R; Kesting MR; Weber M
    Front Oncol; 2021; 11():720951. PubMed ID: 34368002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.